» Authors » Jeffrey S Wefel

Jeffrey S Wefel

Explore the profile of Jeffrey S Wefel including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 129
Citations 7913
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
11.
Cowan B, Olivier K, Tombal B, Wefel J
Adv Ther . 2023 Nov; 41(2):476-491. PMID: 37979089
Cognitive impairment (CI) is an issue that needs to be at the forefront of unmet healthcare needs in patients with prostate cancer (PCa) as it can negatively impact quality of...
12.
Holdhoff M, Nicholas M, Peterson R, Maraka S, Liu L, Fischer J, et al.
Neurooncol Adv . 2023 Aug; 5(1):vdad087. PMID: 37554223
Background: Procaspase-3 (PC-3) is overexpressed in various tumor types, including gliomas. Targeted PC-3 activation combined with chemotherapy is a novel strategy for treating patients with high-grade gliomas, with promising preclinical...
13.
Catalino M, Noll K, Wefel J, Michener H, Prinsloo S, Tummala S, et al.
J Neurosurg . 2023 Jul; 140(1):18-26. PMID: 37439490
Objective: Patients with low-grade glioma (LGG) in eloquent regions often present with seizures, and findings on detailed neuropsychological testing are often abnormal. This study evaluated the association between cortical excitability,...
14.
Altan M, Wang Y, Song J, Welsh J, Tang C, Guha-Thakurta N, et al.
J Immunother Cancer . 2023 Jul; 11(7). PMID: 37402581
Background: Up to 20% of patients with non-small cell lung cancer (NSCLC) develop brain metastasis (BM), for which the current standard of care is radiation therapy with or without surgery....
15.
Gondi V, Deshmukh S, Brown P, Wefel J, Armstrong T, Tome W, et al.
Int J Radiat Oncol Biol Phys . 2023 May; 117(3):571-580. PMID: 37150264
Purpose: Initial report of NRG Oncology CC001, a phase 3 trial of whole-brain radiation therapy plus memantine (WBRT + memantine) with or without hippocampal avoidance (HA), demonstrated neuroprotective effects of...
16.
Gregory T, Mastall M, Lin H, Hess K, Yuan Y, Garcia M, et al.
Neurooncol Adv . 2023 Apr; 5(1):vdad032. PMID: 37114244
Background: Medulloblastoma in adults is rare and treatment decisions are largely driven from pediatric literature. We sought to characterize recurrent medulloblastoma in adults. Methods: From a single-institution dataset of 200...
17.
Guran E, Hu J, Wefel J, Chung C, Cata J
Br J Anaesth . 2022 Oct; 129(6):909-922. PMID: 36270848
Patients with cancer may suffer from a decline in their cognitive function after various cancer therapies, including surgery, radiation, and chemotherapy, and in some cases, this decline in cognitive function...
18.
Beer T, Shore N, Morgans A, Winters-Stone K, Wefel J, George D
BJUI Compass . 2022 Oct; 3(6):424-433. PMID: 36267196
Context: Second-generation androgen receptor inhibitors (ARIs) extend metastasis-free survival, prolong overall survival, and delay symptoms when added to androgen deprivation therapy for the treatment of castration-sensitive or castration-resistant prostate cancer...
19.
Wefel J, Woods S
Neurooncol Pract . 2022 Jul; 9(4):253-254. PMID: 35859540
No abstract available.
20.
Lassman A, Pugh S, Wang T, Aldape K, Gan H, Preusser M, et al.
Neuro Oncol . 2022 Jul; 25(2):339-350. PMID: 35849035
Background: Approximately 50% of newly diagnosed glioblastomas (GBMs) harbor epidermal growth factor receptor gene amplification (EGFR-amp). Preclinical and early-phase clinical data suggested efficacy of depatuxizumab mafodotin (depatux-m), an antibody-drug conjugate...